According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
Borghetti, A., Mondi, A., Piccoli, B., Gagliardini, R., Lamonica, S., Ciccarelli, N., D'Avino, A., Pallavicini, F., Cauda, R., De Luca, A., Fabbiani, M., Di Giambenedetto, S., Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre, Abstract de <<HIV Drug Therapy Glasgow Congress 2014>>, (Glasgow, 02-06 November 2014 ), <<JOURNAL OF THE INTERNATIONAL AIDS SOCIETY>>, 2014; 17 (4 Suppl 3): 19817-19817. 10.7448/IAS.17.4.19817 [http://hdl.handle.net/10807/61162]
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
Borghetti, Alberto;Mondi, Annalisa;Gagliardini, Roberta;Ciccarelli, Nicoletta;D'Avino, Alessandro;Pallavicini, Federico;Cauda, Roberto;De Luca, Andrea;Fabbiani, Massimiliano;Di Giambenedetto, Simona
2014
Abstract
According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
